Alarm sounded on copycat drugs regulation
News | 17 June 2012
When Amgen, the biotechnology group, announced last year that it was teaming up with Watson Pharmaceuticals, a rival maker of generic drugs, to make ...
Click on the link to read the full article at Financial Times
(This link will open in a new window)
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
